Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The STEPs educational framework for medicines management: using mnemonics to reduce harm.

British journal of nursing (Mark Allen Publishing)·2026
Same author

Proteasome inhibition enhances lysosome-mediated targeted protein degradation.

Cell death & disease·2026
Same author

Hypochlorous Acid-Gated Hydrolysis of a Phosphinate Ester Dye in Living Cells.

Journal of the American Chemical Society·2025
Same author

Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines.

British journal of haematology·2025
Same author

Ventilator-Assisted Preoxygenation for Patients With Diabetic Ketoacidosis: A Novel Case Series.

Air medical journal·2025
Same author

Proteasome Inhibition Enhances Lysosome-mediated Targeted Protein Degradation.

bioRxiv : the preprint server for biology·2025
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

New agents for AML and MDS.

Steven Grant1

  • 1Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, Richmond, VA 23298-0035, USA. stgrant@vcu.edu

Best Practice & Research. Clinical Haematology
|December 5, 2009
PubMed
Summary
This summary is machine-generated.

New combination therapies offer hope for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients. Despite diverse treatments, outcomes remain poor for many, especially older or relapsed individuals.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Related Experiment Videos

Last Updated: Jun 18, 2026

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are heterogeneous hematologic malignancies.
  • Current treatments include cytotoxic agents, signal transduction modulators, cell-cycle inhibitors, and epigenetic therapies.
  • Despite therapeutic advances, patient outcomes remain challenging, particularly for older, relapsed, or genetically high-risk individuals.

Purpose of the Study:

  • To review novel therapeutic agents, approaches, and combinations for AML and MDS.
  • To highlight potential strategies for improving treatment efficacy in challenging patient populations.

Main Methods:

  • Literature review of recent advancements in AML and MDS treatment.
  • Focus on combination chemotherapy strategies utilizing new therapeutic agents.
  • Analysis of agents targeting diverse molecular pathways.

Main Results:

  • Review of select new agents and combination approaches.
  • Identification of promising strategies for future clinical application.

Conclusions:

  • Combination chemotherapy with novel agents holds significant potential for improving outcomes in AML and MDS.
  • Targeting multiple pathways simultaneously may overcome treatment resistance and improve patient survival.